Relative Bioavailability of 25 mg BI 10773 (Final Formulation) Compared to 25 mg BI 10773 XX (Trial Formulation 2) Following Oral Administration in Healthy Male and Female Volunteers (an Open-label, Randomised, Single-dose, Two-way Crossover Study).

Trial Profile

Relative Bioavailability of 25 mg BI 10773 (Final Formulation) Compared to 25 mg BI 10773 XX (Trial Formulation 2) Following Oral Administration in Healthy Male and Female Volunteers (an Open-label, Randomised, Single-dose, Two-way Crossover Study).

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Jul 2014

At a glance

  • Drugs Empagliflozin (Primary)
  • Indications Diabetes mellitus
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 14 Jan 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Nov 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top